Biotech Intelligence
Daily analysis of funding, clinical trials, market moves, and company news, drawn from public sources.
Citius Oncology Taps $37M Debt Bet on LYMPHIR Launch, Equity Dilution Avoided
Avenue Capital Group provides non-dilutive runway as the company commercializes its approved CTCL therapy without testing public markets.
SOPHiA GENETICSSOPHiA GENETICS taps public markets for $50M as AI diagnostics platform gains ground
SOPHiA GENETICS (SOPH) priced a $50 million public offering on June 16, 2026. The Swiss health-tech firm, valued at $377 million, will use the proceeds to scale its AI-driven cloud platform for precision oncology. Shares gained 6.3% on the announcement.
Eloxx’s $66M Nasdaq uplisting bets on readthrough drugs
Eloxx Pharmaceuticals raised $66 million in a public offering and uplisted to Nasdaq on June 8, 2026. The cash injection will advance ELX-02, its lead candidate for nonsense mutation-driven rare diseases, into later-stage trials. The move gives the company broader investor access but comes with significant dilution risk.
IDEAYA's $300M Offering Preps Cash for Pivotal Targeted Oncology Data
IDEAYA Biosciences priced a $300 million public offering, bolstering its balance sheet ahead of two major Phase 3 trials. The raise capitalizes on a recent stock run-up and positions the company to fully fund darovasertib and IDE397 through pivotal data and potential launches.
$21M Series A fuels Basata’s AI push into personalized cancer vaccines
Cairo-based Basata raised $21 million in Series A funding led by Basis Set Ventures. The capital will accelerate AI-driven design of patient-specific cancer vaccines amid a global race to commercialize neoantigen platforms.
Novo NordiskNovo Nordisk's Wegovy ADA Data Shows GLP-1s' Reach Beyond Obesity
Novo Nordisk will present Wegovy data at ADA 2026, with post hoc analyses suggesting broader cardiometabolic benefits including in obstructive sleep apnea and liver health. The readouts could bolster the $193B company's case for expanded labels against rivals like Eli Lilly's tirzepatide.
Ingenix Lands $14M to Fuel ‘Modality Fusion’ CRISPR Platform
Ingenix, a U.S.-based gene editing startup, raised a $14 million Series A led by Sofinnova Partners to advance its Modality Fusion platform, which pairs CRISPR with tissue-specific delivery. The raise comes as gene therapy pioneers face pricing and manufacturing headwinds, and Ingenix will need to show it can move beyond platform promises into a pipeline that tackles diseases like sickle cell and Duchenne.
Accro BioscienceOrbiMed backs Accro's RIPK, TYK2/JAK1 pipeline with $50M Series C
Accro Bioscience raised $50 million in a Series C round led by OrbiMed. The funds will support clinical development of its ‘regulated cell death’ platform, including a TYK2/JAK1 inhibitor for ulcerative colitis and a RIPK-targeting drug for psoriasis. With FDA clearance for a Phase II multiregional trial, Accro is extending its reach beyond China.
Neuromodulation Startup NinaMED Raises $14M to Challenge Medtronic in OAB
NinaMED, developing a minimally invasive neuromodulation therapy for overactive bladder, has raised $14 million in Series A funding. The round, announced alongside partner EBT Medical, will advance the licensed NINA system toward pivotal trials. The investment arrives as acquirers pay premiums for OAB devices, the latest being Boston Scientific’s $3.7 billion Axonics buyout.
AccurayAccuray's 10-Year UW Tie Bets Adaptive Radiotherapy Can Resuscitate a $33M Market Cap
Accuray (ARAY), valued at just $33M, signed a 10-year master research agreement with UW-Madison to deploy its Stellar adaptive radiotherapy platform. The partnership aims to generate real-world evidence for personalized cancer care at a time when the Swiss device maker fights for relevance against Varian and Elekta.